

**CONTENT OF THE RESOLUTIONS
OF THE ORDINARY GENERAL MEETING
CAPTOR THERAPEUTICS S.A.
26 JUNE 2023**

RESOLUTION No. 1
OF THE ORDINARY GENERAL MEETING
OF THE COMPANY UNDER THE BUSINESS NAME "CAPTOR THERAPEUTICS" SPÓŁKA AKCYJNA
WITH ITS REGISTERED OFFICE IN WROCŁAW ("THE COMPANY")
OF 26 JUNE 2023
ON APPOINTING THE CHAIR OF THE ORDINARY GENERAL MEETING OF THE COMPANY

§ 1

The Ordinary General Meeting of the Company hereby appoints Mr. Maciej Wróblewski as the Chair of the Ordinary General Meeting of the Company.

The secret vote involved 2,360,015 shares, representing 56.06% of the Company's share capital, of which 3,446,940 valid votes were cast, including:

- 3,443,830 votes in favor,
- 0 votes against,
- 3,110 votes abstained,
- there were no objections.

The resolution was adopted.

RESOLUTION NO. 2
OF THE ORDINARY GENERAL MEETING
OF THE COMPANY UNDER THE BUSINESS NAME "CAPTOR THERAPEUTICS" SPÓŁKA AKCYJNA
WITH ITS REGISTERED OFFICE IN WROCŁAW ("THE COMPANY")
OF 26 JUNE 2023
ON THE ADOPTION OF THE AGENDA OF THE ORDINARY GENERAL MEETING OF THE COMPANY

§ 1

The Ordinary General Meeting of the Company adopts the agenda of the Ordinary General Meeting of the Company as follows:

1. opening of the Ordinary General Meeting.
2. appointing the Chair of the Ordinary General Meeting.
3. stating that the Ordinary General Meeting has been duly convened and is capable of passing binding resolutions.
4. adoption of the agenda of the Ordinary General Meeting.
5. presenting the financial results of the Company and the Captor Therapeutics S.A. Group.
6. adopting of a resolution giving an opinion on the remuneration report prepared by the Company's Supervisory Board.
7. presenting the report of the Supervisory Board of the Company for 2022 and adoption of a resolution on its approval.
8. reviewing the separate financial statement of Captor Therapeutics S.A. for 2022 and adoption of a resolution on its approval.
9. reviewing of the consolidated financial statement of the Captor Therapeutics S.A. Group for 2022 and adoption of a resolution on its approval.
10. reviewing of the report of the Management Board on operations of Captor Therapeutics S.A. and the Captor Therapeutics S.A. Group for the period from 1 January to 31 December 2022, as contained in the annual report of the Captor Therapeutics S.A. Group, and adoption of a resolution on its approval.
11. adopting of a resolution on the coverage of the net loss for the financial year 2022.
12. adopting of resolutions on granting discharge to all members of the Company's Management Board who served in the 2022 financial year.
13. adopting of resolutions on granting discharge to all members of the Company's Supervisory Board who served in the financial year 2022.
14. closing of the Ordinary General Meeting.

§ 2

The resolution enters into force upon its adoption.

The open vote involved 2,360,015 shares, representing 56.06% of the Company's share capital, of which 3,446,940 valid votes were cast, including:

- 3,446,940 votes in favor,
- 0 votes against,
- 0 votes abstained,
- there were no objections.

The resolution was adopted.

RESOLUTION No. 3
OF THE ORDINARY GENERAL MEETING
OF THE COMPANY UNDER THE BUSINESS NAME: "CAPTOR THERAPEUTICS" SPÓŁKA AKCYJNA
WITH ITS REGISTERED OFFICE IN WROCLAW (THE "COMPANY")
OF 26 JUNE 2023
**ON GIVING AN OPINION ON THE REMUNERATION REPORT PREPARED BY THE SUPERVISORY BOARD OF CAPTOR THERAPEUTICS S.A. FOR THE
YEAR 2022**

§ 1

The Ordinary General Meeting of the Company - after reviewing - gives a positive opinion on the report on the remuneration of the Management Board and the Supervisory Board prepared by the Supervisory Board of Captor Therapeutics S.A. for the period from 1 January 2022 to 31 December 2022.

§ 2

The resolution enters into force upon adoption.

The open vote involved 2,360,015 shares, representing 56.06% of the Company's share capital, of which 3,446,940 valid votes were cast, including:

- 3,429,889 votes in favor,
- 17,051 votes against,
- 0 votes abstained,
- there were no objections.

The resolution was adopted.

RESOLUTION No. 4
OF THE ORDINARY GENERAL MEETING
OF THE COMPANY UNDER THE BUSINESS NAME: "CAPTOR THERAPEUTICS" SPÓŁKA AKCYJNA
WITH ITS REGISTERED OFFICE IN WROCŁAW (THE "COMPANY")
OF 26 JUNE 2023
ON THE APPROVAL OF THE REPORT OF THE SUPERVISORY BOARD OF CAPTOR THERAPEUTICS S.A. FOR THE YEAR 2022

§ 1

The Ordinary General Meeting of the Company - after reviewing - approves the report of the Supervisory Board of Captor Therapeutics S.A. for the period from 1 January 2022 to 31 December 2022.

§ 2

The resolution enters into force upon adoption.

The open vote involved 2,360,015 shares, representing 56.06% of the Company's share capital, of which 3,446,940 valid votes were cast, including:

- 3,446,940 votes in favor,
- 0 votes against,
- 0 votes abstained,
- there were no objections.

The resolution was adopted.

RESOLUTION No. 5
OF THE ORDINARY GENERAL MEETING
OF THE COMPANY UNDER THE BUSINESS NAME: "CAPTOR THERAPEUTICS" SPÓŁKA AKCYJNA
WITH ITS REGISTERED OFFICE IN WROCLAW (THE "COMPANY")
OF 26 JUNE 2023
ON THE APPROVAL OF THE SEPARATE FINANCIAL STATEMENT OF CAPTOR THERAPEUTICS S.A. FOR 2022

Pursuant to Article 393 § 1 and Article 395 § 2 pt. 1 of the Commercial Companies Code, the Ordinary General Meeting of the Company, hereby resolves as follows:

§ 1

The Ordinary General Meeting of the Company - after reviewing - approves the separate financial statement of Captor Therapeutics S.A. for the period from 1 January 2022 to 31 December 2022 showing a net loss of PLN 35,746 thousand and total assets of PLN 110,599 thousand.

§ 2

The resolution enters into force upon adoption.

The open vote involved 2,360,015 shares, representing 56.06% of the Company's share capital, of which 3,446,940 valid votes were cast, including:

- 3,446,940 votes in favor,
- 0 votes against,
- 0 votes abstained,
- there were no objections.

The resolution was adopted.

RESOLUTION No. 6

OF THE ORDINARY GENERAL MEETING

OF THE COMPANY UNDER THE BUSINESS NAME: "CAPTOR THERAPEUTICS" SPÓŁKA AKCYJNA

WITH ITS REGISTERED OFFICE IN WROCŁAW (THE "COMPANY")

OF 26 JUNE 2023

ON THE APPROVAL OF THE CONSOLIDATED FINANCIAL STATEMENT OF THE CAPTOR THERAPEUTICS S.A. GROUP FOR 2022

Pursuant to Article 395 § 5 of the Commercial Companies Code and Article 63c § 4 of the Accounting Act, the Ordinary General Meeting of the Company, hereby resolves as follows:

§ 1

The Ordinary General Meeting of the Company - after reviewing - approves the consolidated financial statement of the Captor Therapeutics S.A. Group for the period from 1 January 2022 to 31 December 2022 showing a net loss of PLN 35,894 thousand and total assets of PLN 113,000 thousand.

§ 2

The resolution enters into force upon adoption.

The open vote involved 2,360,015 shares, representing 56.06% of the Company's share capital, of which 3,446,940 valid votes were cast, including:

- 3,446,940 votes in favor,
- 0 votes against,
- 0 votes abstained,
- there were no objections.

The resolution was adopted.

RESOLUTION No. 7

OF THE ORDINARY GENERAL MEETING

OF THE COMPANY UNDER THE BUSINESS NAME: "CAPTOR THERAPEUTICS" SPÓŁKA AKCYJNA

WITH ITS REGISTERED OFFICE IN WROCŁAW (THE "COMPANY")

OF 26 JUNE 2023

ON THE APPROVAL OF THE REPORT OF THE MANAGEMENT BOARD ON OPERATIONS OF CAPTOR THERAPEUTICS S.A. AND THE CAPTOR THERAPEUTICS S.A. GROUP FOR THE PERIOD FROM 1 JANUARY TO 31 DECEMBER 2022, AS CONTAINED IN THE ANNUAL REPORT OF THE CAPTOR THERAPEUTICS S.A. GROUP.

Pursuant to Article 393 § 1 and Article 395 § 2 pt. 1 of the Commercial Companies Code, the Ordinary General Meeting of the Company, hereby resolves as follows:

§ 1

The Ordinary General Meeting of the Company - after reviewing - approves the report of the Management Board on the activities of Captor Therapeutics S.A. and the Captor Therapeutics S.A. Group for the period from 1 January to 31 December 2022, as contained in the Annual Report of the Captor Therapeutics S.A. Group.

§ 2

The resolution enters into force upon adoption.

The open vote involved 2,360,015 shares, representing 56.06% of the Company's share capital, of which 3,446,940 valid votes were cast, including:

- 3,446,940 votes in favor,
- 0 votes against,
- 0 votes abstained,
- there were no objections.

The resolution was adopted.

RESOLUTION No. 8
OF THE ORDINARY GENERAL MEETING
OF THE COMPANY UNDER THE BUSINESS NAME: "CAPTOR THERAPEUTICS" SPÓŁKA AKCYJNA
WITH ITS REGISTERED OFFICE IN WROCŁAW (THE "COMPANY")
OF 26 JUNE 2023
ON THE COVERAGE OF THE LOSS FOR THE PERIOD FROM 1 JANUARY 2022 TO 31 DECEMBER 2022

Pursuant to Article 395 § 2 pt. 2 of the Commercial Companies Code, the Ordinary General Meeting of the Company, hereby resolves as follows:

§ 1

In view of the fact that Captor Therapeutics S.A. incurred a net loss of PLN 35,746 thousand in the period from 1 January 2022 to 31 December 2022, the Ordinary General Meeting resolves to cover the loss from future profits of Captor Therapeutics S.A.

§ 2

The resolution enters into force upon adoption.

The open vote involved 2,360,015 shares, representing 56.06% of the Company's share capital, of which 3,446,940 valid votes were cast, including:

- 3,446,940 votes in favor,
- 0 votes against,
- 0 votes abstained,
- there were no objections.

The resolution was adopted.

RESOLUTION No. 9
OF THE ORDINARY GENERAL MEETING
OF THE COMPANY UNDER THE BUSINESS NAME: "CAPTOR THERAPEUTICS" SPÓŁKA AKCYJNA
WITH ITS REGISTERED OFFICE IN WROCŁAW (THE "COMPANY")
OF 26 JUNE 2023
**ON GRANTING A DISCHARGE TO MR. THOMAS SHEPHERD IN RESPECT OF THE PERFORMANCE OF HIS DUTIES AS A MEMBER OF THE
MANAGEMENT BOARD OF THE COMPANY**

Pursuant to Article 393 § 1 and Article 395 § 2 pt. 3 of the Commercial Companies Code, the Ordinary General Meeting of the Company hereby resolves as follows:

§ 1

The Ordinary General Meeting of the Company grants Mr. Thomas Shepherd a discharge in respect of the performance of his duties as a member of the Management Board of Captor Therapeutics S.A. for the period from 1 January 2022 to 31 December 2022.

§ 2

The resolution enters into force upon adoption.

The secret vote involved 2,360,015 shares, representing 56.06% of the Company's share capital, of which 3,446,940 valid votes were cast, including:

- 3,446,940 votes in favor,
- 0 votes against,
- 0 votes abstained,
- there were no objections.

The resolution was adopted.

RESOLUTION No. 10
OF THE ORDINARY GENERAL MEETING
OF THE COMPANY UNDER THE BUSINESS NAME: "CAPTOR THERAPEUTICS" SPÓŁKA AKCYJNA
WITH ITS REGISTERED OFFICE IN WROCŁAW (THE "COMPANY")
OF 26 JUNE 2023
**ON GRANTING A DISCHARGE TO MR. MICHAŁ WALCZAK IN RESPECT OF THE PERFORMANCE OF HIS DUTIES AS A MEMBER OF THE
MANAGEMENT BOARD OF THE COMPANY**

Pursuant to Article 393 § 1 and Article 395 § 2 pt. 3 of the Commercial Companies Code, the Ordinary General Meeting of the Company, hereby resolves as follows:

§ 1

The Ordinary General Meeting of the Company grants Mr. Michał Walczak a discharge in respect of the performance of his duties as a member of the Management Board of Captor Therapeutics S.A. for the period from 1 January 2022 to 31 December 2022.

§ 2

The resolution enters into force upon adoption.

The secret vote involved 1,404,887 shares, representing 33.37% of the Company's share capital, of which 1,950,795 valid votes were cast, including:

- 1,950,795 votes in favor,
- 0 votes against,
- 0 votes abstained,
- there were no objections,
- Shareholder Michał Walczak did not participate in the vote.

The resolution was adopted.

RESOLUTION No. 11
OF THE ORDINARY GENERAL MEETING
OF THE COMPANY UNDER THE BUSINESS NAME: "CAPTOR THERAPEUTICS" SPÓŁKA AKCYJNA
WITH ITS REGISTERED OFFICE IN WROCŁAW (THE "COMPANY")
OF 26 JUNE 2023
**ON GRANTING A DISCHARGE TO MR. RADOSŁAW KRAWCZYK IN RESPECT OF THE PERFORMANCE OF HIS DUTIES AS A MEMBER OF THE
MANAGEMENT BOARD OF THE COMPANY**

Pursuant to Article 393 § 1 and Article 395 § 2 pt. 3 of the Commercial Companies Code, the Ordinary General Meeting of the Company, hereby resolves as follows:

§ 1

The Ordinary General Meeting of the Company grants Mr. Radosław Krawczyk a discharge in respect of the performance of his duties as a member of the Management Board of Captor Therapeutics S.A. for the period from 1 January 2022 to 31 December 2022.

§ 2

The resolution enters into force upon adoption.

The secret vote involved 2,360,015 shares, representing 56.06% of the Company's share capital, of which 3,446,940 valid votes were cast, including:

- 3,446,940 votes in favor,
- 0 votes against,
- 0 votes abstained,
- there were no objections.

The resolution was adopted.

RESOLUTION No. 12

OF THE ORDINARY GENERAL MEETING

OF THE COMPANY WITH THE BUSINESS NAME: "CAPTOR THERAPEUTICS" SPÓŁKA AKCYJNA

WITH ITS REGISTERED OFFICE IN WROCŁAW (THE "COMPANY")

OF 26 JUNE 2023

ON GRANTING A DISCHARGE TO MR. PAWEŁ HOLSTINGHAUSEN HOLSTEN IN RESPECT OF THE PERFORMANCE OF HIS DUTIES AS A MEMBER OF THE SUPERVISORY BOARD OF THE COMPANY

Pursuant to Article 393 § 1 and Article 395 § 2 pt. 3 of the Commercial Companies Code, the Ordinary General Meeting of the Company, hereby resolves as follows:

§ 1

The Ordinary General Meeting of the Company grants Mr. Paweł Holstinghausen Holsten a discharge in respect of the performance of his duties as a member of the Supervisory Board of Captor Therapeutics S.A. for the period from 1 January 2022 to 31 December 2022.

§ 2

The resolution enters into force upon adoption.

The secret vote involved 1,770,049 shares, representing 42.05% of the Company's share capital, of which 2,496,899 valid votes were cast, including:

- 2,496,899 votes in favor,
- 0 votes against,
- 0 votes abstained,
- there were no objections,
- Shareholder Paul Holstinghausen Holsten did not participate in the vote.

The resolution was adopted.

RESOLUTION No 13

OF THE ORDINARY GENERAL MEETING

OF THE COMPANY UNDER THE BUSINESS NAME: "CAPTOR THERAPEUTICS" SPÓŁKA AKCYJNA

WITH ITS REGISTERED OFFICE IN WROCŁAW (THE "COMPANY")

OF 26 JUNE 2023

ON GRANTING A DISCHARGE TO MR. ROBERT FLORCZYKOWSKI IN RESPECT OF THE PERFORMANCE OF HIS DUTIES AS A MEMBER OF THE SUPERVISORY BOARD OF THE COMPANY

Pursuant to Article 393 § 1 and Article 395 § 2 pt. 3 of the Commercial Companies Code, the Ordinary General Meeting of the Company, hereby resolves as follows:

§ 1

The Ordinary General Meeting of the Company grants Mr. Robert Florczykowski a discharge in respect of the performance of his duties as a member of the Supervisory Board of Captor Therapeutics S.A. for the period from 5 January 2022 to 31 December 2022.

§ 2

The resolution enters into force upon adoption.

The secret vote involved 2,360,015 shares, representing 56.06% of the Company's share capital, of which 3,446,940 valid votes were cast, including:

- 3,446,940 votes in favor,
- 0 votes against,
- 0 votes abstained,
- there were no objections.

The resolution was adopted.

RESOLUTION No. 14

OF THE ORDINARY GENERAL MEETING

OF THE COMPANY UNDER THE BUSINESS NAME: "CAPTOR THERAPEUTICS" SPÓŁKA AKCYJNA

WITH ITS REGISTERED OFFICE IN WROCLAW (THE "COMPANY")

OF 26 JUNE 2023

ON GRANTING A DISCHARGE TO MR. FLORENT GROS IN RESPECT OF THE PERFORMANCE OF HIS DUTIES AS A MEMBER OF THE SUPERVISORY BOARD OF THE COMPANY

Pursuant to Article 393 § 1 and Article 395 § 2 pt. 3 of the Commercial Companies Code, the Ordinary General Meeting of the Company, hereby resolves as follows:

§ 1

The Ordinary General Meeting of the Company grants Mr. Florent Gros a discharge in respect of the performance of his duties as a member of the Supervisory Board of Captor Therapeutics S.A. for the period from 1 January 2022 to 31 December 2022.

§ 2

The resolution enters into force upon adoption.

The secret vote involved 2,360,015 shares, representing 56.06% of the Company's share capital, of which 446,940 valid votes were cast, including:

- 3,446,940 votes in favor,
- 0 votes against,
- 0 votes abstained,
- there were no objections.

The resolution was adopted.

RESOLUTION No. 15
OF THE ORDINARY GENERAL MEETING
OF THE COMPANY WITH THE BUSINESS NAME: "CAPTOR THERAPEUTICS" SPÓŁKA AKCYJNA
WITH ITS REGISTERED OFFICE IN WROCLAW (THE "COMPANY")
OF 26 JUNE 2023
**ON GRANTING A DISCHARGE TO MR. KRZYSZTOF SAMOTIJ IN RESPECT OF THE PERFORMANCE OF HIS DUTIES AS A MEMBER OF THE
SUPERVISORY BOARD OF THE COMPANY**

Pursuant to Article 393 § 1 and Article 395 § 2 pt. 3 of the Commercial Companies Code, the Ordinary General Meeting of the Company, hereby resolves as follows:

§ 1

The Ordinary General Meeting of the Company grants Mr. Krzysztof Samotij a discharge in respect of the performance of his duties as a member of the Supervisory Board of Captor Therapeutics S.A. for the period from 1 January 2022 to 31 December 2022.

§ 2

The resolution enters into force upon adoption.

The secret vote involved 2,360,015 shares, representing 56.06% of the Company's share capital, of which 3,446,940 valid votes were cast, including:

- 3,446,940 votes in favor,
- 0 votes against,
- 0 votes abstained,
- there were no objections.

The resolution was adopted.

RESOLUTION No. 16
OF THE ORDINARY GENERAL MEETING
OF THE COMPANY UNDER THE BUSINESS NAME: "CAPTOR THERAPEUTICS" SPÓŁKA AKCYJNA
WITH ITS REGISTERED OFFICE IN WROCLAW (THE "COMPANY")
OF 26 JUNE 2023
**ON GRANTING A DISCHARGE TO MR. MACIEJ WRÓBLEWSKI IN RESPECT OF THE PERFORMANCE OF HIS DUTIES AS A MEMBER OF THE
SUPERVISORY BOARD OF THE COMPANY**

Pursuant to Article 393 § 1 and Article 395 § 2 pt. 3 of the Commercial Companies Code, the Ordinary General Meeting of the Company, hereby resolves as follows:

§ 1

The Ordinary General Meeting of the Company grants Mr. Maciej Wróblewski a discharge in respect of the performance of his duties as a member of the Supervisory Board of Captor Therapeutics S.A. for the period from 1 January 2022 to 31 December 2022.

§ 2

The resolution enters into force upon adoption.

The secret vote involved 2,356,905 shares, representing 55.99% of the Company's share capital, of which 3,443,830 valid votes cast, including:

- 3,443,830 votes in favor,
- 0 votes against,
- 0 votes abstained,
- there were no objections,
- Shareholder Maciej Wróblewski did not participate in the vote.

The resolution was adopted.